WO2009027843A3 - Techniques pour définir l'indication d'un nouveau composé et pour redéfinir l'indication d'un médicament - Google Patents

Techniques pour définir l'indication d'un nouveau composé et pour redéfinir l'indication d'un médicament Download PDF

Info

Publication number
WO2009027843A3
WO2009027843A3 PCT/IB2008/003162 IB2008003162W WO2009027843A3 WO 2009027843 A3 WO2009027843 A3 WO 2009027843A3 IB 2008003162 W IB2008003162 W IB 2008003162W WO 2009027843 A3 WO2009027843 A3 WO 2009027843A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
pharmaceutical compound
repurposing
purposing
techniques
Prior art date
Application number
PCT/IB2008/003162
Other languages
English (en)
Other versions
WO2009027843A2 (fr
Inventor
Tali Eilam Zoref
Zvia Agur
Original Assignee
Optimata Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimata Ltd. filed Critical Optimata Ltd.
Priority to EP08828648A priority Critical patent/EP2156320A4/fr
Publication of WO2009027843A2 publication Critical patent/WO2009027843A2/fr
Priority to US12/621,175 priority patent/US8489336B2/en
Publication of WO2009027843A3 publication Critical patent/WO2009027843A3/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé pour redéfinir l'indication d'un composé pharmaceutique. Le procédé consiste à identifier un composé pharmaceutique correspondant, soit à un médicament dont la mise au point clinique n'a pas abouti, soit à un médicament approuvé. On crée un modèle mathématique décrivant les processus physiologiques se rapportant à au moins une affection ainsi qu'aux effets du composé pharmaceutique sur l'affection. Le modèle subit des ajustements en fonction des informations provenant des essais précliniques ou cliniques. On suggère, soit un nouveau protocole thérapeutique permettant de sauver le médicament non abouti, soit une nouvelle façon d'utiliser un médicament approuvé. Le protocole thérapeutique suggéré s'affiche.
PCT/IB2008/003162 2002-09-16 2008-05-19 Techniques pour définir l'indication d'un nouveau composé et pour redéfinir l'indication d'un médicament WO2009027843A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08828648A EP2156320A4 (fr) 2007-05-18 2008-05-19 Techniques pour définir l'indication d'un nouveau composé et pour redéfinir l'indication d'un médicament
US12/621,175 US8489336B2 (en) 2002-09-16 2009-11-18 Techniques for purposing a new compound and for re-purposing a drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92453307P 2007-05-18 2007-05-18
US60/924,533 2007-05-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/662,345 Continuation-In-Part US7970550B2 (en) 2002-09-16 2003-09-16 Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV

Publications (2)

Publication Number Publication Date
WO2009027843A2 WO2009027843A2 (fr) 2009-03-05
WO2009027843A3 true WO2009027843A3 (fr) 2009-12-30

Family

ID=40387949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003162 WO2009027843A2 (fr) 2002-09-16 2008-05-19 Techniques pour définir l'indication d'un nouveau composé et pour redéfinir l'indication d'un médicament

Country Status (2)

Country Link
EP (1) EP2156320A4 (fr)
WO (1) WO2009027843A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11164657B2 (en) 2017-11-30 2021-11-02 International Business Machines Corporation Accelerated pharmaceutical repurposing by finding anticorrelations and by text mining
CA3186693A1 (fr) * 2020-07-19 2022-01-27 Inderpreet JALLI Systeme et procede pour developper une therapie medicamenteuse alternative au moyen des caracteristiques d'une therapie medicamenteuse existante pour produire un comportement de voie analogu

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020038310A1 (en) * 2000-07-17 2002-03-28 Reitberg Donald P. Single-patient drug trials used with accumulated database: genomic markers
US20030186244A1 (en) * 2002-03-26 2003-10-02 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US20040107084A1 (en) * 2002-09-16 2004-06-03 Optimata Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020038310A1 (en) * 2000-07-17 2002-03-28 Reitberg Donald P. Single-patient drug trials used with accumulated database: genomic markers
US20030186244A1 (en) * 2002-03-26 2003-10-02 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US20040107084A1 (en) * 2002-09-16 2004-06-03 Optimata Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV

Also Published As

Publication number Publication date
EP2156320A4 (fr) 2010-12-15
EP2156320A2 (fr) 2010-02-24
WO2009027843A2 (fr) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2007014105A3 (fr) Methode et systeme pour adapter un programme de traitement de radiotherapie en fonction d'un modele biologique
EP2073188A3 (fr) Suivi de l'administration de médicaments
WO2007011930A3 (fr) Systemes, interfaces utilisateur et procedes de traitement de donnees medicales
WO2006037802A8 (fr) Procede et systeme d'autogestion de maladie
WO2006002211A3 (fr) Systeme et procede visant a aider un partenaire de soin a surveiller un patient souffrant d'une maladie chronique
WO2007038135A3 (fr) Methode et appareil pour positionner une trame de reference
BRPI0909894A2 (pt) "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
WO2007146426A3 (fr) Nanobilles pour délivrance de médicament
EP1717722A3 (fr) Système et procédé d'identification précoce des precautions d'emploi pour de nouveaux médicaments
WO2005070081A3 (fr) Methodes d'utilisation de la zonisamide comme therapie d'appoint des crises d'epilepsie partielle
PL2330527T3 (pl) Układ i sposób określania informacji dotyczących podawania leków
HK1126416A1 (zh) 檢測藥物對患者的成效的系統和方法
NO20075857L (no) Grafisk visningsanrodning for medisineringsgrenser og leveringsprogram
FI20045392A (fi) Sykemittari, menetelmä ja tietokoneohjelmistotuote
WO2007049164A3 (fr) Systeme interactif de soins aux patients
EP1739585A3 (fr) Système d'identification de médicaments pré-livrés
WO2004044693A3 (fr) Systeme et procede de mise en correspondance de patients et d'essais cliniques medicaux
WO2013012492A3 (fr) Système d'analyse de sinus aérien et de cavité nasale
WO2009027703A3 (fr) Identification d'une lésion d'un organe
WO2005070077A3 (fr) Procedes d'utilisation de zonisamide comme traitement auxiliaire pour des crises partielles
WO2009027843A3 (fr) Techniques pour définir l'indication d'un nouveau composé et pour redéfinir l'indication d'un médicament
EP4011395A4 (fr) Procédé d'identification d'un patient sensible aux médicaments à base de glucides chez des patients atteints de la maladie d'alzheimer
DE602007012684D1 (de) Vorrichtung zur arzneimittelverabreichung und/oder überwachung des zustandes eines patienten
WO2007106369A3 (fr) Systèmes et procédés de dépistage
National Collaborating Centre for Primary Care (UK Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease [Internet]

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828648

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008828648

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE